Nama's AI scorecard currently rates Kestra Medical Technologies Sell (4.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does KMTS report earnings?

Kestra Medical Technologies's next scheduled report is on Dec 14, 2026. Analysts expect EPS of -$0.60.

What is the KMTS price target?

The median analyst price target from 8 analysts is $30.00, with a range of $28.00 – $34.00.

Is KMTS Shariah compliant?

Nama's AAOIFI-style screen reads Kestra Medical Technologies as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Kestra Medical Technologies (KMTS)

Healthcare · Medical Instruments Supplies · NASDAQ

Kestra Medical Technologies (KMTS) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $1.72B and a free-cash-flow yield of -7.5%. Over the most recent reported fiscal year, revenue grew 59.0%. Nama's AI scorecard rates it Sell, 4.0 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 4.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Middle · +1.5% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-9.8%

How far the last close sits under the highest price of the past five years.

Market cap	$1.72B
Trailing P/E	—
Price / book	7.7
Price / sales	16.1
FCF yield	-7.5%
Dividend yield	—
Gross margin	53.9%
Operating margin	-134.5%
Net margin	-140.4%
Revenue growth (YoY)	+59.0%
Revenue growth (3-yr annual)	+131.9%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	—
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Instruments Supplies

KMTS earnings

Next report: Dec 14, 2026 (Q2 2027, EPS estimate -$0.60). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q1 2027	Sep 14, 2026	-$0.46	-$0.62	+25.8%	$30.97M
Q4 2026	Jul 14, 2026	-$0.49	-$0.58	+15.5%	$28.64M
Q3 2026	Mar 17, 2026	-$0.40	-$0.60	+33.3%	$24.55M
Q2 2026	Dec 11, 2025	-$0.45	-$0.56	+19.6%	$22.57M

KMTS analyst price target

Median target $30.00 from 8 analysts, ranging $28.00 – $34.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live KMTS data on Nama Insights →

KMTS FAQ

Is KMTS a buy?: Nama's AI scorecard currently rates Kestra Medical Technologies Sell (4.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does KMTS report earnings?: Kestra Medical Technologies's next scheduled report is on Dec 14, 2026. Analysts expect EPS of -$0.60.
What is the KMTS price target?: The median analyst price target from 8 analysts is $30.00, with a range of $28.00 – $34.00.
Is KMTS Shariah compliant?: Nama's AAOIFI-style screen reads Kestra Medical Technologies as Not Shariah Compliant. At least one of the three ratios or the industry test failed.